Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Edwards Lifesciences ( (EW) ) is now available.
On August 6, 2025, Edwards Lifesciences announced that the U.S. Federal Trade Commission has moved to block its proposed acquisition of JenaValve Technology. Edwards disagrees with this decision, believing it limits treatment options for aortic regurgitation patients and plans to continue pursuing regulatory approval. Despite the FTC’s action, Edwards has revised its full-year 2025 financial guidance, increasing its adjusted EPS forecast to the high-end of $2.45-$2.55, with minimal impact on Q3 guidance.
The most recent analyst rating on (EW) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on Edwards Lifesciences stock, see the EW Stock Forecast page.
Spark’s Take on EW Stock
According to Spark, TipRanks’ AI Analyst, EW is a Outperform.
Edwards Lifesciences’ strong financial health and positive earnings call sentiments are the most significant factors driving the stock score. However, high valuation metrics and operational efficiency challenges slightly dampen the outlook. The company’s strategic corporate events support a favorable long-term view.
To see Spark’s full report on EW stock, click here.
More about Edwards Lifesciences
Edwards Lifesciences is a leading global company in structural heart innovations, focusing on improving patient lives through breakthrough technologies and partnerships with healthcare stakeholders.
Average Trading Volume: 4,413,555
Technical Sentiment Signal: Buy
Current Market Cap: $46.48B
For detailed information about EW stock, go to TipRanks’ Stock Analysis page.